Brief: Eagle Pharmaceuticals Provides 2022 Business Update And Announces Launch Of Vasopressin
05/01/2022 18:44
Jan 5 (Reuters) - Eagle Pharmaceuticals Inc:
* EAGLE PHARMACEUTICALS PROVIDES 2022 BUSINESS UPDATE AND
ANNOUNCES LAUNCH OF VASOPRESSIN
* EAGLE PHARMACEUTICALS INC - VASOPRESSIN SHIPMENTS
SCHEDULED TO
COMMENCE JANUARY 17, 2022
* EAGLE PHARMACEUTICALS INC - ON TRACK TO SUBMIT NEW DRUG
APPLICATION ("NDA") IN FIRST HALF OF 2022, SEEKING APPROVAL OF
LANDIOLOL
* EAGLE PHARMACEUTICALS INC - COMPANY IS PREPARING TO BEGIN
CLINICAL TRIALS FOR CAL02 LATER THIS YEAR
* EAGLE PHARMACEUTICALS INC - WILL COMMENCE HUMAN PILOT
STUDIES OF
ITS FULVESTRANT PRODUCT CANDIDATE SHORTLY
Source text for Eikon: urn:newsml:reuters.com:*:nBw5SlZHKa
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq